<DOC>
	<DOCNO>NCT02546440</DOCNO>
	<brief_summary>The main objective trial investigate whether oral treatment patient suffer cutaneous T cell lymphoma dimethylfumarate lead significant improvement modify severity assessment tool ( mSWAT ) value skin 24 week treatment ( primary endpoint ) . Secondary endpoint CTCL severity index , dermatologic life quality index , itch measure VAS blood involvement applicable . Primary : safety efficacy DMF treatment CTCL Secondary : CTCL severity index , Dermatologic Life Quality index , VAS itching , blood involvement appl .</brief_summary>
	<brief_title>Study Therapy With Dimethylfumarate ( DMF ) Patients With Cutaneous T Cell Lymphoma ( CTCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Histopathologically confirm Mycosis fungoides Sézary syndrome ( CTCL stage ≥ Ib accord EORTCISCL consensus classification ) study entry progressive , persistent recurrent disease Pretreatment topical steroid and/or local PUVA , PUVA possible anymore unsatisfactory response PUVA respectively . Patients history first line systemic treatment ( interferone bexarotene ) may include study Karnofsky index ≥70 % ( accord Karnofsky DA , Burchenal JH . ( 1949 ) . `` The Clinical Evaluation Chemotherapeutic Agents Cancer . '' In : MacLeod CM ( Ed ) , Evaluation Chemotherapeutic Agents . Columbia Univ Press . Page 196 ) Life expectancy &gt; 3 month Age ≥ 18 year Adequate organ function ( differential blood count , liver enzymes , serum creatinine , electrolytes lipid show normal value , history restriction cardiac , kidney liver function ) Negative Pregnancy test urine , agreement efficient contraception male female patient unless infertility document ( DMF approve pregnancy ) Ability understand character individual consequence clinical trial provide write informed consent participate study write informed consent must give accord ICH/GCP , national/local regulation , patient registration prior study specific procedure . Another active malignant disease Topical chemotherapy , superficial radiotherapy , photopheresis systemic CTCL treatment within 28 day study therapy initiation Severe systemic disease infection study therapy initiation Prior treatment DMF simultaneous topical DMF treatment Contraindications treatment DMF ( know hypersensibility drug , severe gastrointestinal disease ( like ulceration ) , Alcohol abuse , liver nephrotoxic medication , know clinically apparent renal hepatic insufficiency ) Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Participation clinical study within 14 day study therapy initiation Pregnant lactating patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>